ChemExpress Subsidiary 2Y-Biopharma Completes U.S. FDA Pre-Approval Inspection with No Form 483 Observations
ChemExpress’ drug product GMP site, 2Y-Biopharma, completed a U.S. FDA PAI with no Form 483 observations and received its EIR. SHANGHAI, SHANGHAI, CHINA, August 18, 2026 /EINPresswire.com/ -- 2Y-Biopharma, a wholly owned subsidiary of Shanghai Haoyuan …